Lighthouse Pharmaceuticals’ plan to become a beacon of hope for Alzheimer’s disease patients has received almost $50 million ...

Dr. Curtis Schreiber led the study at CMH’s Missouri Memory Center, which was one of only 12 clinics nationwide selected to ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2025 on Thursday, August 28, 2025, at 08:00 a.m. CET.

Biogen has lagged the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on the stock’s ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...

Biogen reported 7% year-on-year revenue growth and 4% non-GAAP earnings per share growth. Sales of Leqembi (for Alzheimer's disease) in the US were $63 million, or 21% sequential growth ...

Erin Kelly, from Queensland, Australia, recently learned she had the disease after inheriting a rare genetic mutation called ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance dosing for those with early Alzheimer’s disease, Eisai Co. Ltd. and Biogen Inc.